Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Apligraf scheduled for FDA advisory panel review

Dec. 24, 1997

Life Medical Sciences terminates Piliel trials early; refocuses R&D efforts

Dec. 22, 1997

Antiacne activity of oral contraceptives

Dec. 19, 1997

AEterna's psoriasis agent moves to phase I/II in Canada

Dec. 18, 1997

First biologic approved for treatment of diabetic foot ulcers

Dec. 18, 1997

PAF antagonist demonstrates antipruritic activity in patients with atopic dermatitis

Dec. 18, 1997

First U.S. trials of Zemaphyte to begin

Dec. 17, 1997

Once-daily tacalcitol vs. twice-daily calcipotriol for chronic plaque psoriasis

Dec. 17, 1997

Bard to distribute ProCyte's wound care products

Dec. 17, 1997

Gliatech's ADCON-L recommended for approval

Dec. 15, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.